Search RHCG Website
Select your language

Pain in children, management in the ED

What's New

09/02/2022 Due to a supply issue with diamorphine, the ED Consultant Group, Stephen Bowhay (Lead Clinical Pharmacist) and Senior ED Nursing Group have created a guideline for the use of Intranasal Fentanyl which has replaced the guidance for Intranasal Diamorphine - see below.

Objectives

  • Recognise pain in children and provide analgesia for moderate & severe pain within 20 minutes of arrival in the Emergency Department
  • In treating pain, attention should be paid to other factors distressing the child such as fear of unfamiliar environment and people, parental distress, people in uniforms, needle avoidance, fear of injury severity etc.

Scope

Patients presenting to the Paediatric Emergency Department. 

Audience

Medical and nursing staff in the Paediatric Emergency Department.

November 2023: This guidance is currently under review as it has gone beyond the standard review date. It reflects best practice at the time of authorship / last review and remains safe for use. If there are any concerns regarding the content then please consult with senior clinical staff to confirm.

Introduction
  • Pain in children can be difficult to assess (for example the child may not appear distressed or have difficulty describing / admitting to pain). This can lead to pain being under-recognised, under-treated and treatment being delayed. Drug choice and dosage may also cause problems in those not used to treating children due to unfamiliarity.
Pain assessment
  • Pain assessment should be repeated frequently to ensure adequate response to any intervention.
  • In the Emergency Department of the Royal Hospital for Sick Children, it is the experience of the Triage Nurse that is used to gauge the severity of a child’s pain, based on their observation and feedback from parents.

For example:

  No Pain Mild Pain Moderate Pain Severe Pain
Behaviour Normal activity 
No↓ in movement 
Happy
Rubbing affected area 
Decreased movement 
Neutral expression 
Able to talk/play normally
Protective of affected area 
↓movement / quiet 
Complaining of pain 
Consolable crying 
Grimaces when affected part moved / touched
No movement or defensive of affected part 
Looking frightened 
Very quiet
Restless, unsettled 
Complaining of lots of pain Inconsolable crying
Injury example*   Abrasion / small laceration Ankle sprain 
Minor head injury
Small burn / scald 
Undisplaced limb #
Fingertip injury 
Appendicitis
Displaced limb # # dislocation 
Larger burns/scalds Appendicitis 
Sickle crisis

* Example of injury is only intended as a guide – cases should be assessed on an individual basis

Algorithm for treatment of acute pain in children in the Emergency Department

If child is being admitted and is likely to need ongoing analgesia for moderate / severe pain, consider contacting pain relief nurse specialist (page 8133/ ext. 86920) or duty anaesthetist (page 8602).

Other ways to manage pain
  • Psychological strategies: involving parents, cuddles, child-friendly environment, and explanation with reassurance all help build trust. Also, distraction with toys, blowing bubbles, reading, portable DVD players or story-telling can help to alleviate pain.
  • Non-pharmacological adjuncts such as limb immobilisation for fractures and dressings for burns.
Guideline for using intranasal FENTANYL in the Emergency Department

- to be used in conjunction with Emergency Department Pain Management guideline

Indications:

To be included as part of the first-line treatment of severe pain in a child (without IV access). 
For example, in children with pain secondary to:
 - Clinically suspected limb fractures
 - Painful/distressing burns

Contraindications:
  • Need for immediate IV access (use parenteral morphine)
  • Significant nasal trauma
  • Blocked nose or upper respiratory tract infection
  • Age < 1 year (or weight < 10kg)
  • General contraindications/sensitivity to fentanyl or other opioid use
  • Significant head injury
  • MAOI anti-depressant within 14 days
Adverse Effects:
  • Adverse effects are uncommon, but may include:
  • Respiratory depression
  • Hypotension
  • Nausea and vomiting
  • Itch
  • Chest wall rigidity (only reported in rapid large IV doses)
Protocol:
  1. Weigh the child in kg, attach monitor for continuous O2 saturations
  2. Draw up calculated dose of Fentanyl according to weight
  3. Attach atomiser (MAD device WolfeTory ®) to the 1ml syringe (if total calculated dose over 1ml then draw up additional dose volume in another 1ml syringe)
  4. Position patient either sitting up at 45° or with head to one side
  5. Administer dose by inserting into nostril loosely and aim for centre of nasal cavity prior to squirting
  6. If the dose is > 0.6mL, split dose between both nostrils to prevent loss of solution by sneezing or swallowing.
  7. Depress the plunger quickly
  8. Hold atomiser in place for further 5 seconds to prevent medication from dribbling out of nostril
  9. Don’t forget to give supplementary oral analgesia (if not contra-indicated) and that the child may need ongoing IV analgesia once the initial pain is controlled
  10. Continue 02 sats monitoring for at least 1 hour post administration
  11. Therapeutic levels are reached within 2 minutes and may last for up to 30 minutes. The dose can be repeated after 30 minutes if adequate analgesia is not achieved after the first dose.
Intranasal FENTANYL guideline for dosing and administration

Dose = approximately 1.5 micrograms/kg (repeat after 30mins if needed)

Preparation: Fentanyl injection 50 micrograms in 1ml (CD) (dilution not required)

Weight of child (kg)

Dose (micrograms)
(rounded to nearest whole number)

Dose volume (to 1 decimal place)

10

15

0.3 ml

13

20

0.4 ml

15

25

0.5 ml

20

30

0.6 ml

25

40

0.8 ml

30

45

0.9 ml

35

55

1.1 ml

40

60

1.2 ml

45

70

1.4 ml

50

75

1.5 ml

55

85 

1.7 ml

60

90

1.8 ml

Approved by RHC ED Consultant group with approval from RHC Drugs and Therapeutics Committee pending: February 2022

Editorial Information

Last reviewed: 09 February 2022

Next review: 30 April 2024

Author(s): Dr Joanne Stirling (Consultant in Paediatric Emergency Medicine, RHCG), Correspondence author - Dr Steve Foster (Consultant in Paediatric Emergency Medicine, RHCG)

Co-Author(s): Stakeholder: Mr Stephen Bowhay (Lead Clinical Pharmacist, RHCG)

Approved By: Paediatric Drugs and Therapeutics Committee, RHCG. RHC ED clinical governance group, RHCG